| Not Yet Recruiting | RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy NCT07218692 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcino NCT07500831 | Qilu Hospital of Shandong University | N/A |
| Recruiting | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy NCT06863311 | Karie Runcie | Phase 2 |
| Recruiting | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Ot NCT07227415 | Pfizer | Phase 1 / Phase 2 |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment o NCT07239596 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcin NCT07113977 | Wei Guan | EARLY_Phase 1 |
| Recruiting | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer NCT06399419 | Osel, Inc. | Phase 1 |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Suspended | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial NCT05928806 | Michael B. Atkins, MD | Phase 2 |
| Recruiting | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860 | Mayo Clinic | Phase 2 |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748 | NiKang Therapeutics, Inc. | Phase 2 |
| Recruiting | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor C NCT05967533 | University of California, Davis | Phase 1 |
| Recruiting | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors NCT05868174 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 |
| Recruiting | Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che NCT05703854 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of ST-1898 in Advanced Renal Cell Carcinoma NCT06127238 | Beijing Scitech-Mq Pharmaceuticals Limited | Phase 1 / Phase 2 |
| Recruiting | First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patien NCT05759923 | Molecure S.A. | Phase 1 |
| Active Not Recruiting | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2 NCT05522231 | Hutchmed | Phase 2 / Phase 3 |
| Terminated | IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced NCT05641545 | SLK Kliniken Heilbronn GmbH | Phase 1 |
| Active Not Recruiting | A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced NCT05361434 | Ipsen | — |
| Completed | A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal NCT05444933 | Ipsen | — |
| Withdrawn | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy NCT04941365 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Recruiting | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Pa NCT05092373 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) NCT05262413 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer NCT05239533 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma NCT05135832 | Herlev and Gentofte Hospital | N/A |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cance NCT05122546 | City of Hope Medical Center | Phase 1 |
| Terminated | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT05119335 | NiKang Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination Wit NCT05394493 | Pfizer | — |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma NCT04522323 | MedImmune LLC | Phase 1 |
| Active Not Recruiting | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) f NCT04071223 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma NCT04203901 | CoImmune | Phase 2 |
| Completed | Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma NCT03229083 | University of Rochester | N/A |
| Completed | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study NCT03707574 | National Cancer Institute (NCI) | — |
| Completed | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer NCT03829111 | City of Hope Medical Center | Phase 1 |
| Completed | A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients W NCT03696407 | Ipsen | — |
| Active Not Recruiting | Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic NCT03647878 | Ipsen | — |
| Completed | Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea NCT02156895 | Pfizer | — |
| Completed | CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcino NCT03428217 | Calithera Biosciences, Inc | Phase 2 |
| Completed | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma NCT03339219 | Takeda | Phase 2 |
| Completed | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal NCT03200717 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal NCT03117309 | Michael B. Atkins, MD | Phase 2 |
| Active Not Recruiting | PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer NCT02735252 | University of California, San Francisco | N/A |
| Completed | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell NCT02231749 | Bristol-Myers Squibb | Phase 3 |
| Completed | Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC NCT02143492 | Argos Therapeutics | — |
| Terminated | Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma NCT01727336 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Phase 2 |
| Terminated | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcin NCT01582672 | Argos Therapeutics | Phase 3 |
| Completed | Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Tr NCT01664182 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma NCT01513187 | Spanish Oncology Genito-Urinary Group | Phase 1 / Phase 2 |
| Unknown | Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carci NCT01381822 | Threshold Pharmaceuticals | Phase 1 |
| Completed | An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in NCT01076010 | AVEO Pharmaceuticals, Inc. | Phase 3 |
| Completed | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma NCT01030783 | AVEO Pharmaceuticals, Inc. | Phase 3 |
| Completed | AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination NCT00853372 | Amgen | Phase 2 |
| Completed | Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Su NCT00486538 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib NCT00467025 | Amgen | Phase 2 |
| Completed | Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Re NCT00494091 | Pfizer | Phase 2 |
| Completed | A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma NCT00422019 | Amgen | Phase 2 |
| Completed | Dendritic Cell Based Therapy of Renal Cell Carcinoma NCT00197860 | Inge Marie Svane | Phase 1 / Phase 2 |
| Completed | Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment NCT00425204 | Amgen | Phase 2 |
| Completed | Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2 NCT00425035 | Amgen | Phase 2 |